Literature DB >> 28640706

Adult Glioblastoma.

Brian M Alexander1, Timothy F Cloughesy1.   

Abstract

Glioblastoma (GBM) is a rare tumor and one of the most challenging malignancies to treat in all of oncology. Although advances have been made in the treatment of GBM, encouraging outcomes typically are not observed; patients diagnosed with these tumors generally have a dismal prognosis and poor quality of life as the disease progresses. This review summarizes the clinical presentation of GBM, diagnostic methods, evidentiary basis for the current standards of care, and investigational approaches to treat or manage GBM. Because the track record for developing effective therapies for GBM has been dismal, we also review the challenges to successful therapeutic and biomarker development.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28640706     DOI: 10.1200/JCO.2017.73.0119

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  202 in total

Review 1.  Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Authors:  Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

Review 2.  Multiple strategies to improve the therapeutic efficacy of oncolytic herpes simplex virus in the treatment of glioblastoma.

Authors:  Zhengjun Zhou; Junjie Tian; Wenyan Zhang; Wei Xiang; Yang Ming; Ligang Chen; Jie Zhou
Journal:  Oncol Lett       Date:  2021-05-03       Impact factor: 2.967

3.  Features of diffuse gliomas that are misdiagnosed on initial neuroimaging: a case control study.

Authors:  M D Maldonado; P Batchala; D Ornan; C Fadul; D Schiff; J N Itri; R Jain; S H Patel
Journal:  J Neurooncol       Date:  2018-06-29       Impact factor: 4.130

Review 4.  Enabling biodegradable functional biomaterials for the management of neurological disorders.

Authors:  Dingying Shan; Chuying Ma; Jian Yang
Journal:  Adv Drug Deliv Rev       Date:  2019-06-20       Impact factor: 15.470

5.  Circadian regulator NR1D2 regulates glioblastoma cell proliferation and motility.

Authors:  Min Yu; Wenjing Li; Qianqian Wang; Yan Wang; Fei Lu
Journal:  Oncogene       Date:  2018-05-18       Impact factor: 9.867

6.  Personalized therapeutic delivery in the neurosurgical operating room.

Authors:  Michael A Vogelbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-20       Impact factor: 11.205

7.  Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth.

Authors:  Jiange Qiu; Qianqian Li; Katherine A Bell; Xue Yao; Yifeng Du; Erik Zhang; Jane J Yu; Ying Yu; Zhi Shi; Jianxiong Jiang
Journal:  Br J Pharmacol       Date:  2019-04-29       Impact factor: 8.739

8.  The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?

Authors:  Alyssa M Vanderbeek; Rifaquat Rahman; Geoffrey Fell; Steffen Ventz; Tianqi Chen; Robert Redd; Giovanni Parmigiani; Timothy F Cloughesy; Patrick Y Wen; Lorenzo Trippa; Brian M Alexander
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

Review 9.  The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology.

Authors:  Daniel N Cagney; Joohee Sul; Raymond Y Huang; Keith L Ligon; Patrick Y Wen; Brian M Alexander
Journal:  Neuro Oncol       Date:  2018-08-02       Impact factor: 12.300

10.  Targeted Brain Tumor Radiotherapy Using an Auger Emitter.

Authors:  Giacomo Pirovano; Stephen A Jannetti; Lukas M Carter; Ahmad Sadique; Susanne Kossatz; Navjot Guru; Paula Demétrio De Souza França; Masatomo Maeda; Brian M Zeglis; Jason S Lewis; John L Humm; Thomas Reiner
Journal:  Clin Cancer Res       Date:  2020-02-17       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.